SG11201903795WA - Salts of indazole derivative and crystals thereof - Google Patents

Salts of indazole derivative and crystals thereof

Info

Publication number
SG11201903795WA
SG11201903795WA SG11201903795WA SG11201903795WA SG11201903795WA SG 11201903795W A SG11201903795W A SG 11201903795WA SG 11201903795W A SG11201903795W A SG 11201903795WA SG 11201903795W A SG11201903795W A SG 11201903795WA SG 11201903795W A SG11201903795W A SG 11201903795WA
Authority
SG
Singapore
Prior art keywords
international
crystals
pct
salts
eisai
Prior art date
Application number
SG11201903795WA
Inventor
Keiko Onuma
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of SG11201903795WA publication Critical patent/SG11201903795WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 31 May 2018 (31.05.2018) WIPO I PCT ill~~~~~~~~ 011101010VIIIOH olo omoimo im million° ow (10) International Publication Number WO 2018/097273 Al (51) International Patent Classification: C07D 401/10 (2006.01) (21) International Application Number: PCT/JP2017/042335 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) (22) International Filing Date: 27 November 2017 (27.11.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 2016-229635 28 November 2016 (28.11.2016) JP (71) Applicant: EISAI R&D MANAGEMENT CO., LTD. [JP/JP]; 4-6-10 Koishikawa, Bunkyo-ku, Tokyo, 1128088 (JP). (72) Inventor: ONUMA Keiko; C/O Eisai Co., Ltd. Tsukuba Research Laboratories, 5-1-3 Tokodai, Tsukuba-shi, Ibara- ki, 3002635 (JP). (74) Agent: HASEGAWA Yoshiki et al.; SOEI PATENT AND LAW FIRM, Marunouchi MY PLAZA (Meiji Yasuda Life Bldg.) 9th fl., 1-1, Marunouchi 2-chome, Chiyoda-ku, Tokyo, 1000005 (JP). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (54) Title: SALTS OF INDAZOLE DERIVATIVE AND CRYSTALS THEREOF 0 H (I) (57) : The present invention provides salts of (E)-N,N-dimethy1-44245-((Z)-4,4,4-trifluoro-1-(3-fluoro-1H-indazol-5-y1)-2- phenylbut-1-en-l-yppyridin-2-yl)oxy)ethyl)amino)but-2-enamide represented by the formula I and acids, and crystals thereof, possess- ing a potential to be used as drug substance in pharmaceuticals.
SG11201903795WA 2016-11-28 2017-11-27 Salts of indazole derivative and crystals thereof SG11201903795WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016229635 2016-11-28
PCT/JP2017/042335 WO2018097273A1 (en) 2016-11-28 2017-11-27 Salts of indazole derivative and crystals thereof

Publications (1)

Publication Number Publication Date
SG11201903795WA true SG11201903795WA (en) 2019-05-30

Family

ID=62195940

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201903795WA SG11201903795WA (en) 2016-11-28 2017-11-27 Salts of indazole derivative and crystals thereof

Country Status (14)

Country Link
US (1) US10640483B2 (en)
EP (1) EP3544967B1 (en)
JP (1) JP6346368B1 (en)
KR (1) KR102425785B1 (en)
CN (1) CN109790141B (en)
AU (1) AU2017363699B2 (en)
BR (1) BR112019008489A2 (en)
CA (1) CA3041986A1 (en)
ES (1) ES2954879T3 (en)
IL (1) IL266003B (en)
MX (1) MX2019004967A (en)
RU (1) RU2747399C2 (en)
SG (1) SG11201903795WA (en)
WO (1) WO2018097273A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2747399C2 (en) 2016-11-28 2021-05-04 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Indazole derivative salts and their crystals
WO2019225552A1 (en) * 2018-05-22 2019-11-28 Eisai R&D Management Co., Ltd. Salts of indazole derivative and crystals thereof
EP3780510B1 (en) 2018-06-06 2023-02-22 Nippon Telegraph And Telephone Corporation Optical line terminal and band allocation method
MX2021014349A (en) 2019-05-24 2022-01-06 Eisai R&D Man Co Ltd A method for treating cancer with an oral dosage form of an estrogen receptor-alpha inhibitor.
JP2023548340A (en) 2020-11-06 2023-11-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 How to treat breast cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3907290A1 (en) 1989-03-07 1990-09-13 Gerhard Prof Dr Eisenbrand STEROID HORMONE RECEPTOR AFFINES ANTITUARY ACTIVE SUBSTANCES
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
WO2009120999A2 (en) 2008-03-28 2009-10-01 Olema Pharmaceuticals, Inc. Use of an endoxifen prodrug for treatment of breast cancer
US8063249B1 (en) 2008-04-25 2011-11-22 Olema Pharmaceuticals, Inc. Substituted triphenyl butenes
WO2011046596A2 (en) 2009-10-13 2011-04-21 Duquesne University Of The Holy Spirit, A Nonprofit Corporation Organized Under The Laws Of The Commonwealth Of Pennsylvania Anti-cancer tamoxifen-melatonin hybrid ligand
MX2012005994A (en) 2009-12-04 2012-08-08 Taisho Pharmaceutical Co Ltd 2-pyridone compounds.
US8222416B2 (en) 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
WO2011129837A1 (en) 2010-04-16 2011-10-20 Olema Pharmaceuticals, Inc. Use of a 4-hydroxytoremifene prodrug for treatment of breast cancer
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
ES2540996T3 (en) * 2010-12-13 2015-07-15 Array Biopharma, Inc. Compounds of substituted N- (1H-indazol-4-yl) imidazo [1,2-a] pyridin-3-carboxamide as type III receptor tyrosine kinase inhibitors
WO2013056178A2 (en) 2011-10-14 2013-04-18 Foundation Medicine, Inc. Novel estrogen receptor mutations and uses thereof
MX2014011217A (en) 2012-03-20 2015-03-10 Seragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof.
US9365510B2 (en) 2012-04-16 2016-06-14 British Columbia Cancer Agency Branch Aziridine bisphenol ethers and related compounds and methods for their use
JOP20200097A1 (en) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc Androgen receptor modulator and uses thereof
MX2015016171A (en) 2013-06-19 2016-08-08 Seragon Pharmaceuticals Inc Azetidine estrogen receptor modulators and uses thereof.
WO2014205138A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Estrogen receptor modulator and uses thereof
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
AU2015228859A1 (en) 2014-03-13 2016-07-07 F. Hoffmann-La Roche Ag Therapeutic combinations with estrogen receptor modulators
WO2016055982A1 (en) 2014-10-10 2016-04-14 Acerta Pharma B.V. Quinoline and quinazoline compounds
US9845291B2 (en) 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof
DK3302471T3 (en) 2015-05-29 2021-11-15 Eisai R&D Man Co Ltd TETRA-SUBSTITUTED ALKENE COMPOUNDS AND THEIR USE
JP2019535778A (en) 2016-11-24 2019-12-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 Tetrasubstituted alkene compounds and their use for treating breast cancer
RU2747399C2 (en) 2016-11-28 2021-05-04 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Indazole derivative salts and their crystals
SG11201908531WA (en) * 2017-03-16 2019-10-30 Eisai R&D Man Co Ltd Combination therapies for the treatment of breast cancer

Also Published As

Publication number Publication date
WO2018097273A1 (en) 2018-05-31
IL266003B (en) 2022-08-01
RU2019112080A (en) 2020-12-28
MX2019004967A (en) 2019-08-22
JP2018108981A (en) 2018-07-12
US10640483B2 (en) 2020-05-05
EP3544967A1 (en) 2019-10-02
KR102425785B1 (en) 2022-07-28
EP3544967A4 (en) 2020-05-20
CA3041986A1 (en) 2018-05-31
RU2747399C2 (en) 2021-05-04
JP6346368B1 (en) 2018-06-20
IL266003A (en) 2019-06-30
RU2019112080A3 (en) 2020-12-28
CN109790141B (en) 2021-06-11
KR20190084941A (en) 2019-07-17
BR112019008489A2 (en) 2019-09-10
AU2017363699A1 (en) 2019-04-18
CN109790141A (en) 2019-05-21
US20190144419A1 (en) 2019-05-16
ES2954879T3 (en) 2023-11-27
EP3544967B1 (en) 2023-06-28
AU2017363699B2 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
SG11201903795WA (en) Salts of indazole derivative and crystals thereof
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201908532UA (en) Macrocyclic compounds as ros1 kinase inhibitors
SG11201906763RA (en) Pyrrolo [1,2-b] pyridazine derivatives
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201909432SA (en) Compounds for increasing genome editing efficiency
SG11201906891RA (en) Methods for the administration of certain vmat2 inhibitors
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201408261UA (en) Syringe
SG11201908640TA (en) Pyrrolidinones and a process to prepare them
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201909011PA (en) Niraparib compositions
SG11201803627XA (en) N-substituted indole derivatives as pge2 receptor modulators
SG11201809830WA (en) Selective reduction of cysteine-engineered antibodies
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201909615YA (en) Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same
SG11202000494UA (en) Drug delivery composition
SG11201900689RA (en) Compounds and compositions and uses thereof
SG11201806480UA (en) Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201407184PA (en) Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals
SG11201809882XA (en) Pharmaceutical combinations for treating cancer